Search Results - "Devanand, Davangere. P."

Computerized cognitive training and functional recovery in major depressive disorder: A meta-analysis by Motter, Jeffrey N, Pimontel, Monique A, Rindskopf, David, Devanand, Davangere P, Doraiswamy, P. Murali, Sneed, Joel R

“…Abstract Objective Depression is common, frequently resistant to antidepressant treatment, and associated with impairments in cognition and everyday…”
Get full text

Olfactory identification deficits and increased mortality in the community by Devanand, Davangere P., Lee, Seonjoo, Manly, Jennifer, Andrews, Howard, Schupf, Nicole, Masurkar, Arjun, Stern, Yaakov, Mayeux, Richard, Doty, Richard L.

“…Objective To examine the association between odor identification deficits and future mortality in a multiethnic community cohort of older adults. Methods…”
Get full text

At the interface of sensory and motor dysfunctions and Alzheimer's disease by Albers, Mark W, Gilmore, Grover C, Kaye, Jeffrey, Murphy, Claire, Wingfield, Arthur, Bennett, David A, Boxer, Adam L, Buchman, Aron S, Cruickshanks, Karen J, Devanand, Davangere P, Duffy, Charles J, Gall, Christine M, Gates, George A, Granholm, Ann-Charlotte, Hensch, Takao, Holtzer, Roee, Hyman, Bradley T, Lin, Frank R, McKee, Ann C, Morris, John C, Petersen, Ronald C, Silbert, Lisa C, Struble, Robert G, Trojanowski, John Q, Verghese, Joe, Wilson, Donald A, Xu, Shunbin, Zhang, Li I

“…Abstract Recent evidence indicates that sensory and motor changes may precede the cognitive symptoms of Alzheimer's disease (AD) by several years and may…”
Get full text

Apolipoprotein E Genotype e2: Neuroprotection and Its Limits by Kim, Hyun, Devanand, Davangere P., Carlson, Scott, Goldberg, Terry E.

“…In this review, we comprehensively, qualitatively, and critically synthesized several features of APOE-e2, a known APOE protective variant, including its…”
Get full text

Combining Early Markers Strongly Predicts Conversion from Mild Cognitive Impairment to Alzheimer's Disease by Devanand, Davangere P, Liu, Xinhua, Tabert, Matthias H, Pradhaban, Gnanavalli, Cuasay, Katrina, Bell, Karen, de Leon, Mony J, Doty, Richard L, Stern, Yaakov, Pelton, Gregory H

“…Background The utility of combining early markers to predict conversion from mild cognitive impairment (MCI) to Alzheimer's Disease (AD) remains uncertain…”
Get full text

Chemosensory deficits are best predictor of serologic response among individuals infected with SARS-CoV-2 by Overdevest, Jonathan B, Irace, Alexandria L, Mazzanti, Valeria, Oh, Eun Jeong, Joseph, Paule V, Devanand, Davangere P, Bitan, Zachary C, Hod, Eldad A, Gudis, David A, Chiuzan, Codruta

“…Smell and taste alteration are closely linked to infection with SARS-CoV-2 and may be associated with a more indolent disease course. Serologic response rates…”
Get full text

Intact global cognitive and olfactory ability predicts lack of transition to dementia by Devanand, Davangere P., Lee, Seonjoo, Luchsinger, Jose A., Andrews, Howard, Goldberg, Terry, Huey, Edward D., Schupf, Nicole, Manly, Jennifer, Stern, Yaakov, Kreisl, William C., Mayeux, Richard

“…Odor identification deficits characterize Alzheimer's disease and other dementias. We examined if intact performance on brief cognitive and odor identification…”
Get full text

Neuropsychiatric Symptoms and Trajectories of Dependence and Cognition in a Sample of Community-dwelling Older Adults with Dementia by Kociolek, Anton J, Fernandez, Kayri K, Hernandez, Michelle, Jin, Zhezhen, Cosentino, Stephanie, Zhu, Carolyn W, Gu, Yian, Devanand, Davangere P, Stern, Yaakov

“…Neuropsychiatric symptoms (NPS), including psychotic symptoms (hallucinations, illusions, delusions), agitation/aggression, and depressed mood, are common in…”
Get more information

Distinct and joint effects of low and high levels of Aβ and tau deposition on cortical thickness by Hani Hojjati, Seyed, Butler, Tracy A., Chiang, Gloria C., Habeck, Christian, RoyChoudhury, Arindam, Feiz, Farnia, Shteingart, Jacob, Nayak, Siddharth, Ozoria, Sindy, Fernández, Antonio, Stern, Yaakov, Luchsinger, José A., Devanand, Davangere P., Razlighi, Qolamreza R.

“…•Early accumulation Aβ deposition is associated with an increase in cortical thickness.•Early accumulation of tau deposition is associated with an increase in…”
Get full text

Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease by Motter, Jeffrey N., Liu, Xinhua, Qian, Min, Cohen, Hannah R., Devanand, Davangere P.

“…Introduction This study evaluated acute change in odor identification following atropine nasal spray challenge, and 8‐week change in odor identification…”
Get full text

Associations Between Neuropsychiatric Symptoms and Neuropathological Diagnoses of Alzheimer Disease and Related Dementias by Devanand, Davangere P, Lee, Seonjoo, Huey, Edward D, Goldberg, Terry E

“…Understanding associations of Alzheimer disease (AD) and related dementias (ADRD) pathologies with common neuropsychiatric symptoms (NPS) may have implications…”
Get more information

Antidepressant Medication and Executive Dysfunction: A Deleterious Interaction in Late-Life Depression by Sneed, Joel R., Ph.D, Culang, Michelle E., B.S, Keilp, John G., Ph.D, Rutherford, Bret R., M.D, Devanand, Davangere P., M.D, Roose, Steven P., M.D

“…Objectives To determine whether there is differential response to placebo or citalopram among older patients with and without deficient response inhibition…”
Get full text

Age-Specific Prevalence and Incidence of Dementia Diagnoses Among Older US Adults With Schizophrenia by Stroup, T Scott, Olfson, Mark, Huang, Cecilia, Wall, Melanie M, Goldberg, Terry, Devanand, Davangere P, Gerhard, Tobias

“…People with schizophrenia are at high risk of receiving a diagnosis of dementia. Understanding the magnitude and timing of this increased risk has important…”
Get more information

Computerized Cognitive Training for Major Depressive Disorder: What's Next? by Motter, Jeffrey N, Devanand, Davangere P, Doraiswamy, P Murali, Sneed, Joel R

Get full text

A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People with Depression and Dementia by Nelson, J. Craig, Devanand, Davangere P.

“…OBJECTIVES: To determine the efficacy of antidepressants in people with depression and dementia. DESIGN: A systematic review and meta‐analysis based on a…”
Get full text

Provisional diagnostic criteria for depression of Alzheimer disease by Olin, Jason T, Schneider, Lon S, Katz, Ira R, Meyers, Barnett S, Alexopoulos, George S, Breitner, John C, Bruce, Martha L, Caine, Eric D, Cummings, Jeffrey L, Devanand, Davangere P, Krishnan, K Ranga Rama, Lyketsos, Constantine G, Lyness, Jeffrey M, Rabins, Peter V, Reynolds, 3rd, Charles F, Rovner, Barry W, Steffens, David C, Tariot, Pierre N, Lebowitz, Barry D

“…The authors, a group of investigators with extensive research and clinical experience related to both late-life depression and Alzheimer disease (AD), propose…”
Get more information

Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial by Luchsinger, José A, Perez, Thania, Chang, Helena, Mehta, Pankaj, Steffener, Jason, Pradabhan, Gnanavalli, Ichise, Masanori, Manly, Jennifer, Devanand, Davangere P, Bagiella, Emilia

“…Diabetes and hyperinsulinemia may be risk factors for Alzheimer's disease (AD). We conducted a pilot study of metformin, a medication efficacious in treating…”
Get more information

Trial of Pimavanserin in Dementia-Related Psychosis by Tariot, Pierre N, Cummings, Jeffrey L, Soto-Martin, Maria E, Ballard, Clive, Erten-Lyons, Deniz, Sultzer, David L, Devanand, Davangere P, Weintraub, Daniel, McEvoy, Bradley, Youakim, James M, Stankovic, Srdjan, Foff, Erin P

“…The serotonin-receptor modulator pimavanserin reduces psychosis in patients with Parkinson’s disease. In a randomized discontinuation trial involving patients…”
Get full text

Vigorous, regular physical exercise may slow disease progression in Alzheimer's disease by Devanand, Davangere P., Masurkar, Arjun V., Wisniewski, Thomas

“…Introduction Mild to moderate exercise may decrease Alzheimer's disease (AD) risk, but the effects of vigorous, regular physical exercise remain unclear…”
Get full text

Comparison of relative change with effect size metrics in Alzheimer’s disease clinical trials by Goldberg, Terry E, Lee, Seonjoo, Devanand, Davangere P, Schneider, Lon S

“…BackgroundPer cent slowing of decline is frequently used as a metric of outcome in Alzheimer’s disease (AD) clinical trials, but it may be misleading. Our…”
Get full text